Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Announces Major FOB Initiative With Its New Business Unit

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck BioVentures plans to launch follow-on version of Amgen’s Aranesp by 2012.
Advertisement

Related Content

Merck Buys Contract Manufacturing Org Avecia To Advance Biologics Strategy
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2009
Merck Adds Biosimilar Capabilities, Insmed Gets Fresh Start In $130M Deal
Fresh Start For Insmed, Added Biosimilar Capabilities For Merck In $130M Deal
Lonza Won’t Compete With Partners In Teva Biosimilars Collaboration
Teva Adds To Biosimilars Capabilities Through Partnership With Lonza
Teva Adds To Biosimilars Capabilities Through Partnership With Lonza
Merck Continues Looking For The “Right” Biotech Buying Opportunity
Merck’s Ambitious Plans For Follow-On Biologics
Merck's Head-long Leap into Follow-On Biologics

Topics

Advertisement
UsernamePublicRestriction

Register

PS067204

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel